CLINICAL TRIALS PROFILE FOR BROMPHENIRAMINE MALEATE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for brompheniramine maleate
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00894634 ↗ | Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2009-03-21 | The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to <12 yrs and adolescents aged 12 to <18 yrs. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for brompheniramine maleate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00894634 ↗ | Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2009-03-21 | The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to <12 yrs and adolescents aged 12 to <18 yrs. |
| NCT01177852 ↗ | Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis | Withdrawn | Ache Laboratorios Farmaceuticos S.A. | Phase 3 | 2011-10-01 | Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-productive cough, daytime/nighttime, with duration for at least 3 and no more than 5 consecutive days (without systemic/topic use of medication during this period) followed by nasal congestion, with or without associate other nasal symptoms (sneezing, runny nose, nasal itching and/or mouth breathing). The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization. |
| NCT01393548 ↗ | Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis | Completed | Ache Laboratorios Farmaceuticos S.A. | Phase 3 | 2014-08-01 | This is a multicenter clinical trial, phase III, non-inferiority, controlled by active medicine, open, randomized, enroll 538 children, 2 to 12 years old, with acute inflammation upper airway, characterized by nasal congestion and runny nose, lasting at least 24 hours and a maximum of 48 hours prior to inclusion. The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization. |
| NCT01393561 ↗ | Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis | Completed | Ache Laboratorios Farmaceuticos S.A. | Phase 3 | 2014-07-01 | This is a multicenter clinical trial, phase III, superiority, controlled by active medicine, double-blind, randomized, enroll 166 children, over 12 years old, with acute inflammation upper airway, characterized by nasal congestion and runny nose, lasting at least 24 hours and a maximum of 48 hours prior to inclusion. The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for brompheniramine maleate
Condition Name
Clinical Trial Locations for brompheniramine maleate
Clinical Trial Progress for brompheniramine maleate
Clinical Trial Phase
Clinical Trial Sponsors for brompheniramine maleate
Sponsor Name
